^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MammaPrint®

    Company:
    Agendia
    Related tests:
    2d
    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (clinicaltrials.gov)
    P3, N=1670, Recruiting, NRG Oncology | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • exemestane
    4d
    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib)
    5d
    Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    MammaPrint®
    |
    paclitaxel • doxorubicin hydrochloride • Irene (pyrotinib) • cyclophosphamide • epirubicin
    19d
    Guiding treatment decisions in early breast cancer: A model-based comparison of the OncotypeDX and MammaPrint tests. (PubMed, Breast)
    Both MammaPrint and OncotypeDX tests improve identifying candidates for chemotherapy among women with early breast cancer, with broadly equivalent clinical usefulness. The tests should be implemented into existing risk algorithms to maximize their clinical usefulness.
    Journal
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    1m
    Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index (clinicaltrials.gov)
    P2, N=64, Recruiting, Shantou Central Hospital | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    MammaPrint®
    |
    albumin-bound paclitaxel
    1m
    MiRaDoR: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (clinicaltrials.gov)
    P2, N=1260, Recruiting, MedSIR | Active, not recruiting --> Recruiting
    Enrollment open • Minimal residual disease • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • PIK3CA mutation
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Verzenio (abemaciclib) • Itovebi (inavolisib) • giredestrant (RG6171)
    2ms
    Advancing breast cancer biomarkers: a centromere-related gene signature integrated with single-cell analysis for prognostic prediction. (PubMed, Front Immunol)
    This study is the first to establish a CENP-based prognostic model for BC, offering novel biomarkers and potential therapeutic targets for personalized treatment. Additionally, the biological function of the key molecule MMP1 was validated through both in vitro and in vivo experiments.
    Journal • Gene Signature
    |
    MMP1 (Matrix metallopeptidase 1) • CENPA (Centromere protein A)
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    2ms
    Neoadjuvant Immunotherapy in Hormone Receptor-Positive Breast Cancer: From Tumor Microenvironment Reprogramming to Combination Therapy Strategies. (PubMed, Int J Mol Sci)
    We demonstrate that optimal efficacy requires biomarker-guided patient selection integrating genetic and TME features, precise sequencing, and a mechanistic understanding of drug-specific immunomodulatory effects. The integration of platform trial designs (I-SPY2, CheckMate-7FL) with composite biomarker algorithms represents a paradigm shift toward precision neoadjuvant immunotherapy, offering a conceptual framework for transforming outcomes in molecularly defined HR+ breast cancer subsets.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency)
    |
    PD-L1 expression • HR positive • HRD • TMB-L
    |
    MammaPrint®
    3ms
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group
    New P3 trial
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Orserdu (elacestrant)
    3ms
    Pathological examination in breast oncology: Overview of histological types, examination procedures, predictive and innovative biomarkers (PubMed, Ann Chir Plast Esthet)
    Innovative approaches such as liquid biopsy and next-generation sequencing (NGS) enable minimally invasive monitoring and personalized care, especially in advanced disease. Breast cancer pathology is thus a dynamic, integrative discipline central to precision oncology, driven by ongoing technological and molecular advances, and essential to multidisciplinary cancer care.
    Review • Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • PIK3CA mutation • HRD • ESR1 mutation • BRCA mutation
    |
    MammaPrint®
    3ms
    Predicting MammaPrint Recurrence Risk from Breast Cancer Pathological Images Using a Weakly Supervised Transformer. (PubMed, Adv Sci (Weinh))
    Prognostic evaluation in the external cohort exhibits significant stratification of distant metastasis risk (HR: 3.14, p-value = 0.0014), underscoring the prognostic power of CPMP. These findings demonstrate the capability of CPMP in MP risk prediction, offering a flexible supplement to genomic risk assessment in early-stage BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    MammaPrint®
    3ms
    Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer. (PubMed, BMC Cancer)
    High HER2 intensity and HER2 intrinsic subtype could be a means for predicting achievement of pCR. The findings indicate the essential role of MP/BP subtyping in the treatment of HER2 + BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive
    |
    MammaPrint®